The Most-Favored-Nation Policy: Outlook and Implications Beyond U.S.
The Most-Favored-Nation Policy: Outlook and Implications Beyond U.S.
Published on PharmExec
On May 12, 2025, U.S. President Donald Trump signed an Executive Order introducing a “Most Favored Nation (MFN)” drug pricing policy, accompanied by a White House Fact Sheet. This initiative seeks to reduce U.S. prescription drug costs by linking domestic prices to those in comparable developed countries.
While this is not President Trump’s first attempt to apply International Reference Pricing (IRP) methodology to regulate drug costs, the MFN Executive Order represents his most sweeping and stringent effort to date.
In this article, we aim to provide:
An overview of the MFN Executive Order and initial industry reactions
An analysis of its potential global implications for pricing and market access
Guidance for pharmaceutical companies navigating the uncertainties ahead
Please click in the link below to read the full article on Pharmexec, written by Anaïs Frappé ; Mark Kohler and Daniel Shapiro.
About the authors
About the Authors: Anaïs Frappé is a Partner; Mark Kohler is a Senior Principal and Daniel Shapiro is an Analyst at Windrose Consulting Group. This article draws upon analytical work and insights provided by Windrose Consulting Group analysts, which informed its content and conclusions.
Please get in touch if you would like to discuss.